Publish Ahead of Print

Original Article

Radiological manifestations, histological features and surgical outcomes of pulmonary meningothelial proliferation: a case series and rethinking
Dong Lin, Yangli Yu, Hao Wang, Yong Fang, Jun Yin, Yaxing Shen, Lijie Tan
CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
Andrea Moreno-Manuel, Eloisa Jantus-Lewintre, Ines Simões, Fernando Aranda, Silvia Calabuig-Fariñas, Esther Carreras, Sheila Zúñiga, Yvonne Saenger, Rafael Rosell, Carlos Camps, Francisco Lozano, Rafael Sirera
Three-dimensional reconstruction/personalized three-dimensional printed model for thoracoscopic anatomical partial-lobectomy in stage I lung cancer: a retrospective study
Bin Qiu, Ying Ji, Huayu He, Jun Zhao, Qi Xue, Shugeng Gao
Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients
Menno Tamminga, Lisa Oomens, T. Jeroen N. Hiltermann, Kiki C. Andree, Arjan Tibbe, Joska Broekmaat, Ed Schuuring, Leon W. M. M. Terstappen, Harry J. M. Groen
Does size matter? A population-based analysis of malignant pleural mesothelioma
Jiaxi He, Songhui Xu, Hui Pan, Shuben Li, Jianxing He
Neoadjuvant chemotherapy combined with intraoperative radiotherapy is effective to prevent recurrence in high-risk non- small cell lung cancer (NSCLC) patients
Olga V. Pankova, Evgeny O. Rodionov, Sergey V. Miller, Sergey A. Tuzikov, Liubov A. Tashireva, Tatiana S. Gerashchenko, Evgeny V. Denisov, Vladimir M. Perelmuter
An easy-to-use scoring system to estimate the survival of patients irradiated for bone metastases from lung cancer
Dirk Rades, Rapha Haus, Stefan Janssen, Steven E. Schild
EGFR circulating tumour DNA testing: Identification of predictors of ctDNA detection and implications for survival outcomes
Alexandra Pender, Curtis Hughesman, Elaine Law, Amadea Kristanti, Kelly McNeil, Selina Wong, Tracy Tucker, Ian Bosdet, Sean Young, Janessa Laskin, Aly Karsan, Stephen Yip, Cheryl Ho
The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
Chao Zhao, Tao Jiang, Jiayu Li, Yan Wang, Chunxia Su, Xiaoxia Chen, Shengxiang Ren, Xuefei Li, Caicun Zhou
Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program
Luca Cantini, Robert A. Belderbos, Cornedine J. Gooijer, Daphne W. Dumoulin, Robin Cornelissen, Sara Baart, Jacobus A. Burgers, Paul Baas, Joachim G. J. V. Aerts
Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors
Sangtian Liu, Fei Zhou, Zhiyu Liu, Anwen Xiong, Yijun Jia, Sha Zhao, Chao Zhao, Xuefei Li, Tao Jiang, Ruoshuang Han, Meng Qiao, Yiwei Liu, Yayi He, Jiayu Li, Wei Li, Guanghui Gao, Shengxiang Ren, Chunxia Su, Caicun Zhou
Recent trends in use of adjuvant chemotherapy in elderly stage II– III non-small cell lung cancer
Takefumi Komiya, Emily Powell, Achuta Kumar Guddati

Review Article

Optimizing lung cancer MDT data for maximum clinical impact—a scoping literature review
Emily Stone, Nicole Rankin, David Currow, Kwun M. Fong, Jane L. Phillips, Tim Shaw
New insights into the interaction of the immune system with non-small cell lung carcinomas
Paul Hofman
Induction treatment in patients with stage III non-small cell lung cancer
Ramón Palmero, Noelia Vilariño, Arturo Navarro-Martín, Ernest Nadal
How should molecular findings be integrated in the classification for lung cancer?
Yin P. Hung, Lucian R. Chirieac
Mediastinal staging for non-small-cell lung cancer
Virginia Leiro-Fernández, Alberto Fernández-Villar
Dose and fractionation schedules in radiotherapy for non-small cell lung cancer
Lucyna Kepka, Joanna Socha
Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
Kenichi Suda, Tetsuya Mitsudomi
Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: ready for practice?
Anton Schreuder, Ernst T. Scholten, Bram van Ginneken, Colin Jacobs
A review on the impact of lung cancer multidisciplinary care on patient outcomes
Monique Y. Heinke, Shalini K. Vinod
Lung cancer screening: who pays? who receives?—the Chinese perspective
Yang Zhang, Haiquan Chen
Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
Lizza E. L. Hendriks, Jordi Remon, Jessica Menis, Benjamin Besse
Challenges and issues surrounding the use for translational research of human samples obtained during the COVID-19 pandemic from lung cancer patients
Paul Hofman
Decade in review: a new era for RET-rearranged lung cancers
Noura J. Choudhury, Alexander Drilon
Multidisciplinary team care in advanced lung cancer
Anna Kowalczyk, Jacek Jassem
Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
Ana Casal-Mouriño, Alberto Ruano-Ravina, María Lorenzo-González, Ángeles Rodríguez-Martínez, Alexandra Giraldo-Osorio, Leonor Varela-Lema, Tara Pereiro-Brea, Juan Miguel Barros-Dios, Luis Valdés-Cuadrado, Mónica Pérez-Ríos
Accuracy of lung cancer staging in the multidisciplinary team setting
Chong-Kin Liam, Yong-Sheng Liam, Mau-Ern Poh, Chee-Kuan Wong
Minimal invasive surgery in locally advanced N2 non-small cell lung cancer
Ana Karina Patané
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
Janna Josephus Anna Oda Schoenmaekers, Marthe Sentijna Paats, Anne-Marie Clasina Dingemans, Lizza Elisabeth Lucia Hendriks
Locally advanced non-small cell lung cancer: the place of specialist thoracic surgery in the multidisciplinary team
Muteb Al Zaidi, Gavin M. Wright
Should sublobar resection be offered for screening-detected lung nodules?
Alan D. L. Sihoe
Patient-derived cell line, xenograft and organoid models in lung cancer therapy
Ku-Geng Huo, Elisa D’Arcangelo, Ming-Sound Tsao
Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer
Olwen Leaman Alcibar, Ernest Nadal, Inmaculada Romero Palomar, Arturo Navarro-Martin
Future perspectives from lung cancer pre-clinical models: new treatments are coming?
Francesca Bersani, Deborah Morena, Francesca Picca, Alessandro Morotti, Fabrizio Tabbò, Paolo Bironzo, Luisella Righi, Riccardo Taulli
Implementation of lung cancer multidisciplinary teams: a review of evidence-practice gaps
Nicole M. Rankin, Elizabeth A. Fradgley, David J. Barnes
Managing of screening-detected sub-solid nodules—a European perspective
Sara Ricciardi, Richard Booton, Renè Horsleben Petersen, Maurizio Infante, Marco Scarci, Giulia Veronesi, Giuseppe Cardillo
Managing screening-detected subsolid nodules—the Asian perspective
Masaaki Sato, Shun-Mao Yang, Dong Tian, Nakajima Jun, Jang-Ming Lee
Earlier multidisciplinary palliative care intervention for people with lung cancer: a systematic review and meta-analysis
Slavica Kochovska, Diana H. Ferreira, Tim Luckett, Jane L. Phillips, David C. Currow
Lung cancer screening: targeting the hard to reach—a review
Guido Van Hal, Paloma Diab Garcia
Challenges in the target volume definition of lung cancer radiotherapy
Susan Mercieca, José S. A. Belderbos, Marcel van Herk


Liquid biopsies in non-small cell lung cancer management: what can we learn from methylation status and mutant allele frequencies?
Gina M. Castellano, Sharon R. Pine
Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
Fabrizio Tabbò, Maria Lucia Reale, Silvia Novello
EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?
Conor E. Steuer, Suresh S. Ramalingam
Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
Surein Arulananda, Thomas John
Radiomics signature for prediction of N2 disease: fascinating but still a long way to go for clinical application
Kwon Joong Na, Hongyoon Choi, Young Tae Kim
Adjuvant EGFR-TKIs-based therapy: are we ready?
Terence Tam
Melting the tip of the iceberg: bronchoscopic-guided transbronchial microwave ablation
Michael A. Pritchett, Charles C. Schirmer, Paul Laeseke
On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
Pierpaolo Correale, Rocco Giannicola, Rita Emilena Saladino, Valerio Nardone, Luigi Pirtoli, Pierfrancesco Tassone, Amalia Luce, Salvatore Cappabianca, Marianna Scrima, Pierosandro Tagliaferri, Michele Caraglia
Cyclin D1 expression in KRAS mutant non-small cell lung cancer—old wine into new skins
Kah Yee Goh, Wan-Teck Lim
Multidisciplinary team care in lung cancer
Emily Stone
Proprotein convertase furin in SARS-CoV-2 and non-small cell lung cancer
Rafael Rosell, Niki Karachaliou, Sara Fancelli, Oscar Arrieta, Giancarlo Troncone, Peng Cao
Biomarkers predictive value in early stage non-small cell lung cancer
Umberto Malapelle, Elena Vigliar, Giancarlo Troncone
Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
Hiroaki Kanemura, Masayuki Takeda, Kazuhiko Nakagawa
Can CT radiomics differentiate benign from malignant N2 adenopathy in non-small cell lung cancer
Robert J. Cerfolio, William H. Moore
The Gut Microbiome and its interaction with health, disease, treatment response and toxicity in patients advanced cancer: focus on lung cancer and immunotherapy
Nadina Tinsley, Natalie Cook
The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients
Mihaela Aldea, Jose Carlos Benitez, Laura Mezquita
Adjuvant TKI treatment of EGFR-mutant lung cancer—already ripe for decision?
Diego Kauffmann-Guerrero
Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined
Christos Chouaïd, Nathalie Baize, Isabelle Monnet

Review Article

New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts
Sylvie Lantuejoul, Lynnette Fernandez-Cuesta, Francesca Damiola, Nicolas Girard, Anne McLeer

Case Report

Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report
Sook Jung Yun, In-Jae Oh, Cheol Kyu Park, Young-Chul Kim, Hyeon Bin Kim, Hee-Kyung Kim, A. Ram Hong, In-Young Kim, Sung-Ja Ahn, Kook-Joo Na, Yoo-Duk Choi

Brief Report

Rates of positive lung cancer screening examinations in academic versus community practice
Louise M. Henderson, Leon Bacchus, Thad Benefield, Roger Huamani Velasquez, M. Patricia Rivera

Editorial Commentary

Finding chinks in the osimertinib resistance armor
Jose Luis Leal, Benjamin Solomon, Thomas John
New fissure-attached nodules in lung cancer screening: more practical implications from the NELSON study?
Helen Morgan, Emma L. O’Dowd, Arjun Nair, David R. Baldwin
PET-Plan: potential for dose escalation by target volume reduction in locally advanced NSCLC
Evelyn E. C. de Jong, Janita E. van Timmeren
Rethought histologic classification of pleural mesothelioma to better treat: go forward from looking back
Philippe Astoul
Perspective of gene therapy with replication competent viruses
Makoto Maemondo
HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
Toshimitsu Yamaoka, Junji Tsurutani, Hironori Sagara, Tohru Ohmori
Alternative splicing of HER2: a novel mediator of EGFR TKI resistance
Zachary A. Yochum, Liza C. Villaruz
Hormone gene signature guides a novel therapeutic opportunity to improve sensitivity to HER family inhibition in lung cancer
Zachary A. Yochum, Laura P. Stabile
FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression
Pamela Abdayem, David Planchard
First-line cytotoxic chemotherapy regimen for non-small cell lung cancer in the elderly population: plus ça change
Grace K. Dy, Maya Khalil, Edwin Yau